Dianthus Therapeutics, Inc. ( DNTH ) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of -25.42% and 102.61%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
| Ticker |
Sentiment |
Impact |
|
CUE
|
Neutral
|
21 %
|
|
DNTH
|
Neutral
|
40 %
|
